"Biomarkers, Tumor" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or BODY FLUIDS. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including HORMONES; ANTIGENS; amino and NUCLEIC ACIDS; ENZYMES; POLYAMINES; and specific CELL MEMBRANE PROTEINS and LIPIDS.
| Descriptor ID |
D014408
|
| MeSH Number(s) |
D23.101.140
|
| Concept/Terms |
Biomarkers, Tumor- Biomarkers, Tumor
- Tumor Biomarkers
- Markers, Biological Tumor
- Tumor Markers, Biological
- Markers, Tumor Metabolite
- Tumor Metabolite Markers
- Metabolite Markers, Tumor
- Marker, Tumor Metabolite
- Metabolite Marker, Tumor
- Tumor Metabolite Marker
- Tumor Markers, Biologic
- Biologic Tumor Markers
- Markers, Biologic Tumor
- Marker, Biologic Tumor
- Biologic Tumor Marker
- Tumor Marker, Biologic
- Biochemical Tumor Markers
- Markers, Biochemical Tumor
- Marker, Biochemical Tumor
- Biochemical Tumor Marker
- Tumor Marker, Biochemical
- Tumor Markers, Biochemical
- Carcinogen Markers
- Markers, Carcinogen
- Markers, Neoplasm Metabolite
- Neoplasm Metabolite Markers
- Marker, Neoplasm Metabolite
- Metabolite Marker, Neoplasm
- Neoplasm Metabolite Marker
- Metabolite Markers, Neoplasm
- Biological Tumor Markers
- Biological Tumor Marker
- Tumor Marker, Biological
- Marker, Biological Tumor
Markers, Tumor- Markers, Tumor
- Tumor Markers
- Biomarkers, Cancer
- Cancer Biomarkers
|
Below are MeSH descriptors whose meaning is more general than "Biomarkers, Tumor".
Below are MeSH descriptors whose meaning is more specific than "Biomarkers, Tumor".
This graph shows the total number of publications written about "Biomarkers, Tumor" by people in this website by year, and whether "Biomarkers, Tumor" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 1 | 1 |
| 1996 | 1 | 2 | 3 |
| 1997 | 3 | 1 | 4 |
| 1998 | 7 | 4 | 11 |
| 1999 | 8 | 2 | 10 |
| 2000 | 5 | 1 | 6 |
| 2001 | 9 | 2 | 11 |
| 2002 | 6 | 9 | 15 |
| 2003 | 13 | 16 | 29 |
| 2004 | 12 | 6 | 18 |
| 2005 | 22 | 15 | 37 |
| 2006 | 17 | 11 | 28 |
| 2007 | 17 | 13 | 30 |
| 2008 | 19 | 16 | 35 |
| 2009 | 22 | 19 | 41 |
| 2010 | 17 | 22 | 39 |
| 2011 | 15 | 25 | 40 |
| 2012 | 22 | 15 | 37 |
| 2013 | 28 | 20 | 48 |
| 2014 | 28 | 18 | 46 |
| 2015 | 40 | 21 | 61 |
| 2016 | 31 | 29 | 60 |
| 2017 | 33 | 20 | 53 |
| 2018 | 34 | 20 | 54 |
| 2019 | 35 | 29 | 64 |
| 2020 | 38 | 25 | 63 |
| 2021 | 33 | 27 | 60 |
| 2022 | 0 | 32 | 32 |
| 2023 | 1 | 11 | 12 |
| 2024 | 6 | 30 | 36 |
| 2025 | 1 | 3 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Biomarkers, Tumor" by people in Profiles.
-
Next-Generation Sequencing-Based MSI Scoring Predicts Benefit in Mismatch Repair-Deficient Tumors Treated with Nivolumab: Follow-up on NCI-MATCH Arm Z1D. Clin Cancer Res. 2025 Feb 17; 31(4):667-677.
-
Improving Individualized Rhabdomyosarcoma Prognosis Predictions Using Somatic Molecular Biomarkers. JCO Precis Oncol. 2025 Feb; 9:e2400556.
-
The Landscape of ctDNA in Appendiceal Adenocarcinoma. Clin Cancer Res. 2025 Feb 03; 31(3):551-560.
-
Antitumor Activity and Biomarker Analysis for TROP2 Antibody-Drug Conjugate Datopotamab Deruxtecan in Patient-Derived Breast Cancer Xenograft Models. Clin Cancer Res. 2025 Feb 03; 31(3):573-587.
-
The Association Between Thyroid Differentiation Score and Survival Outcomes in Papillary Thyroid Carcinoma. J Clin Endocrinol Metab. 2025 Jan 21; 110(2):356-363.
-
Utilizing Patient-Derived Xenografts to Model Precision Oncology for Biliary Tract Cancer. Clin Cancer Res. 2025 Jan 17; 31(2):387-402.
-
Longitudinal multimodal profiling of IDH-wildtype glioblastoma reveals the molecular evolution and cellular phenotypes underlying prognostically different treatment responses. Neuro Oncol. 2025 Jan 12; 27(1):89-105.
-
Lead time trajectory of blood-based protein biomarkers for detection of pancreatic cancer based on repeat testing. Cancer Lett. 2025 Mar 01; 612:217450.
-
The Prognostic Role of HPV or p16INK4a Status in Penile Squamous Cell Carcinoma: A Meta-Analysis. J Natl Compr Canc Netw. 2025 01 03; 23(2).
-
Classification of non-TCGA cancer samples to TCGA molecular subtypes using compact feature sets. Cancer Cell. 2025 Feb 10; 43(2):195-212.e11.